The LabCorp Difference
The LabCorp Difference

Clinical laboratory results influence 70% to 80% of all medical decisions made by health care providers. 

Selecting a quality laboratory that keeps pace with the rapid advances in health care and laboratory medicine helps ensure that health care dollars are spent on the most appropriate treatments and therapies that benefit patients. LabCorp's testing services provide clinical value, building knowledge that can lead to earlier detection, diagnosis, and more effective treatment through quality information, innovation, and convenience.

Quality Information
At the forefront of our service commitment is quality laboratory information, which has its foundation in our standardized laboratory systems and rigorous quality management program. Our primary clinical laboratories utilize the same test codes, specimen requirements, instrumentation, reference ranges and operating procedures. Customers benefit from consistent laboratory information regardless of testing site and the seamless flow of testing information to providers should circumstances make it necessary to move specimens. Our high level of efficiency enables us to offer our customers the most scientifically advanced diagnostic testing at continually competitive rates that help them control their overall medical costs. Standardized laboratory information also facilitates HEDIS reporting as well as disease and patient management initiatives.

LabCorp's reputation and proven record in genomic testing continues to attract scientific leaders and technology pioneers. LabCorp has been at the forefront of new molecular tests to diagnose and manage disease, particularly in the areas of infectious disease, oncology, and genetics. LabCorp figured prominently in the development of polymerase chain reaction (PCR) technology, which is now the basis for many medically important tests, and we were the first commercial laboratory to offer this testing to health care providers. LabCorp also has global expertise in clinical trials and was involved in the original research and subsequent standardization of HER-2/neu testing for breast cancer. 

The availability of routine and esoteric testing through our national network of 29 primary clinical laboratories and seven specialty laboratories, which are accredited by the College of American Pathologists (CAP) and licensed through the Clinical Laboratory Improvement Amendment (CLIA), enhances provider satisfaction. Our national service network also includes more than 1,600 facilities for convenient specimen collection.